Updates in non-small cell lung cancer

Clinical Journal of Oncology Nursing

Volumn 12, Issue 4, 2008, Pages 587-596

  Walker, Suzanne ^a  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER STAGING; CAUSE OF DEATH; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG TUMOR; MALE; MASS SCREENING; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NURSE ATTITUDE; NURSING ASSESSMENT; ONCOLOGY NURSING; PROGNOSIS; REVIEW; RISK FACTOR; SMOKING; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CAUSE OF DEATH; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; NEOPLASM STAGING; NURSE'S ROLE; NURSING ASSESSMENT; ONCOLOGIC NURSING; PNEUMONECTOMY; PROGNOSIS; RISK FACTORS; SMOKING; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 55249094584     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/08.CJON.587-596     Document Type: Article

References (86)

1. Aberle, D.R., & Brown, K. (2008). Lung cancer screening with CT. Clinics in Chest Medicine, 29(1), 1-14.
2. Agency for Healthcare Research and Quality. (2005). Helping smokers quit: A guide for nurses. Rockville, MD: U.S. Department of Health and Human Services.
3. Albain, K.S., Swann, R.S., Rusch, V.R., Turrisi, A.T., Shepherd, F.A., Smith, C.J., et al. (2005). Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): Outcomes update of North America Intergroup 0139 (RTOG 9309) [Abstract 7014]. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, Part I, 23(16S), 624s.
4. Albanes, D., Heinonen, O.P., Huttunen, J.K., Taylor, P.R., Virtamo, J., Edwards, B.K., et al. (1995). Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. American Journal of Clinical Nutrition, 62(6, Suppl.), 1427S-1420S.
5. Alberg, A.J., & Samet, J.M. (2003). Epidemiology of lung cancer. Chest, 123(1, Suppl.), 21S-49S.
6. American Cancer Society. (2007). Can non-small cell lung cancer be found early? Retrieved August 21, 2007, from http://www.cancer.org/docroot/CRI/content/CRI_2_4_3x_Can_Non-Small_Cell_Lung_Cancer_Be_Found_Early.asp?sitearea=
7. Ansari, R.H., Gonin, R., Socinski, M., Edelman, R., Catalano, D., Marinucci, R., et al. (2007). Elderly subgroup analysis of a randomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P), compared to paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC)[Abstract 7665]. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings, Part I, 25(18S), 425s.
8. Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F., Schiller, J., Paesmans, M., et al. (2007). Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. Journal of the National Cancer Institute, 99(11), 847-857.
9. Arriagada, R., Bergman, B., Dunant, A., LeChevalier, T., Pignon, J.P., Vensteenkiste, J., et al. (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. New England Journal of Medicine, 350(4), 351-360.
10. Balko, J.M., Potti, A., Sauners, C., Stromberg, A., Haura, E.B., & Black, E.P. (2006). Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics, 7, 289.
11. Bell, D.W., Lynch, T.J., Haserlat, S.M., Harris, P.L., Okimoto, R.A., Brannigan, B.W., et al. (2005). Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer:Molecular analysis of the IDEAL/INTACT geftinib trials. Journal of Clinical Oncology, 23(31), 8081-8092.
12. Bergman, A.M., Eijk, P.P., van Haperen, R., Veronique, W.T., Smid, K., Veerman, G., et al. (2005). In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide re-ductase subunit M1 as the major determinant. Cancer Research, 65 (20), 9510-9516.
13. Birim, O., Kappetein, A.P., Stijnen, T., & Bogers, A.J. (2005). Meta-analysis of positron emission tomographic and computed tomo-graphic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Annals of Thoracic Surgery, 79 (1), 375-382.
14. Brahmer, J.R., Govindan, R., Novello, S., Rosell, R., Belani, C.P., Atkins, J.N., et al. (2007). Effcacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study [Abstract 7542]. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings, Part I, 25(18S), 395s.
15. Caro, M.M., Laviano, A., & Pichard, C. (2007). Impact of nutrition on quality of life during cancer. Current Opinion in Clinical Nutrition and Metabolic Care, 10(4), 480-487.
16. Centers for Disease Control and Prevention. (2006). Behavioral risk factor surveillance system survey data. Atlanta, GA: U.S. Department of Health and Human Services.
17. Cerfolio, R.J., Ojha, B., Bryant, A.S., Raghuveer, V., Mountz, J.M., & Bartolucci, A.A. (2004). The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with non-small cell lung cancer. Annals of Thoracic Surgery, 78(3), 1017-1023.
18. Cobo, M., Isla, D., Massuti, B., Montes, A., Sanchez, J.M., Provencio, M., et al. (2007). Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer. Journal of Clinical Oncology, 25(19), 2747-2754.
19. Connor, S.R., Pyenson, B., Fitch, K., Spence, C., & Iwasaki, K. (2007). Comparing hospice and nonhospice patient survival among patients who die within a three-year window. Journal of Pain and Symptom Management, 33(3), 238-246.
20. Corner, J., Hopkinson, J., Fitzsimmons, D., Barclay, S., & Muers, M. (2005). Is late diagnosis of lung cancer inevitable? Interview study of patients' recollections of symptoms before diagnosis. Thorax, 60(4), 314-319.
21. Curran, W.J., Scott, C.B., Langer, C.J., Komaki, R., Lee, J.S., Hauser, B., et al. (2003). Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410 [Abstract 2499]. Journal of Clinical Oncology, 2003 ASCO Annual Meeting Proceedings, Part I, 22, 621.
22. Davidson, J.D., Ma, L., Flagella, M., Geeganage, S., Gelbert, L.M., & Slapak, C.A. (2004). An increase in the expression of ribonucle-otide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Research, 64(11), 3761-3766.
23. Degner, L.F., & Sloan, J.A. (1995). Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. Journal of Pain and Symptom Management, 10 (6), 423-431.
24. ®: Dyspnea. Retrieved November 1, 2007, from http://www.ons.org/outcomes/volume2/dyspnea.shtml
25. Douillard, J., Rosell, R., Delena, M., Legroumellec, A., Torres, A., & Carpagnano, F. (2005). ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stageI-III) non-small cell lung cancer (NSCLC) patients (pts): Final results after 70 months of median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. [Abstract 7013]. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, Part I, 23(16S), 624s.
26. Elderly Lung Cancer Vinorelbine Italian Study Group. (1999). Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute, 91(1), 66-72.
27. ® (pemetrexed) [package insert]. Retrieved August 10, 2007, from http://pi.lilly.com/us/alimta-pi.pdf
28. Etter, J.F., & Stapleton, J.A. (2006). Nicotine replacement therapy for long-term smoking cessation: A meta-analysis. Tobacco Control, 15 (4), 280-285.
29. Fehrenbacher, L., O'Neill, V., Belani, C.P., Bonomi, P., Hart, L., Mel-nyk, O., et al. (2006). A phase II mu lticenter, randomized clinical trial to evaluate the effcacy and safet y of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer [Abstract 7062]. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings, Part I, 24(18S), 379s.
30. Furuse, K., Fukuoka, M., Kawahara, M., Nishikawa, H., Takada, Y., & Kudoh, S. (1999). Phase III study of concurrent vs. sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. Journal of Clinical Oncology, 17(9), 2692-2699.
31. Gandara, D.R., Chansky, K., Albain, K.S., Leigh, B.R., Gaspar, L.E, Lara, P.N., Jr., et al. (2003). Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. Journal of Clinical Oncology, 21(10), 2004-2010.
32. Gatzemeier, U., Blumenschein, G., Fosella, F., Simantov, R., Elting, J., Bigwood, F., et al. (2006). Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma [Abstract 7002]. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings, Part I, 24(18S), 364s.
33. Gatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., Brennscheidt, U., et al. (2004). Results of a phase III trial of er-lotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [Abstract 7010]. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition, 22, 23.
34. Gautam, A., & Bepler, G. (2006). Suppression of lung tumor formation by the regulatory sub unit of ribonucleotide reductase. Cancer Research, 66(13), 6497-6502.
35. Ginsberg, R.J., Rubinstein, L.V., & Lung Cancer Study Group. (1995). Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Annals of Thoracic Surgery, 60(3), 615-623.
36. Gonzales, D., Rennard, S.I., Nides, M., Oncken, C., Azoulay, S., Billing, C.B., et al. (2006). Varencicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained release bupro-pion and placebo for smoking cessation. JAMA, 296(1), 47-55.
37. Gridelli, C., Perrone, F., Gallo, C., Cigolari, S., Rossi, A., Piantedosi, F., et al. (2003). Chemotherapy for elderly patients with advanced non-small cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly (MILES) phase III randomized trial. Journal of the National Cancer Institute, 95(5), 362-372.
38. Hamilton, W., Peters, T.J., Round, A., & Sharp, D. (2005). What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax, 60(12), 1059-1065.
39. Hanna, N., Shepherd, F.A., Fossella, F.V., Pereira, J.R., De Marinis, F., von Pawel, J., et al. (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. Journal of Clinical Oncology, 22(9), 1589-1597.
40. Hanna, N.H., Neubauer, M., Ansari, R., Govindan, D., Bruetman, D., Fisher, W., et al. (2007). Phase III tr ial of cisplatin (P) plus etopo -side (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LN 01-24/USO -023 [Abstract 7512]. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings, Part I, 25(18S), 387s.
41. Herbst, R.S., Johnson, D.H., Mininberg, E., Carbone, D.P., Henderson, T., & Kim, E.S. (2005). Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. Journal of Clinical Oncology, 23(11), 2544-2555.
42. Herbst, R.S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B.E., Sandler, A., et al. (2005). TRIBUTE: A phase III trial of er-lotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Journal of Clinical Oncology, 23(25), 5892-5899.
43. Hughes, J.R., Stead, L.F., & Lancaster, T. (2007). Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews, 1, CD000031.
44. Jatoi, A. (2006). Pharmacologic therapy for the cancer anorexia/ weight loss syndrome: A data-driven, practical approach. Journal of Supportive Oncology, 4(10), 499-502.
45. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Taylor, M., et al. (2008). Cancer statistics, 2008. CA: A Cancer Journal for Clinicians, 58 (1), 71-96.
46. Kvale, P.A., Simoff, M., & Prakash, U.B. (2003). Palliative care. Chest, 123(1, Suppl.), 284 S-311S.
47. Langer, C.J., Manola, J., Bernardo, P., Kugler, J.W., Bonomi, P., Cella, D., et al. (2002). Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. Journal of the National Cancer Institute, 94(3), 173-181.
48. Larminat, F., & Bohr, V.A. (1994). Role of the human ERCC-1 gene in gene-specifc repair of cisplatin-induced DNA damage. Nucleic Acids Research, 22(15), 3005-3010.
49. Liu, B., Barrett, T., Choyke, P., Maynard, K., Wright, J., Kummar, S., et al. (2006). A phase II study of BAY 43-9006 (sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC) [Abstract 17119]. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings, Part I, 24(18S), 676s.
50. Marino, P., Pampallona, S., Preatoni, A., Cantoni, A., & Invernizzi, F. (1994). Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest, 106(3), 861-865.
51. McCarthy, E.P., Burns, R., Ngo-Metzger, Q., Davis, R.B., & Phillips, R.S. (2007). Hospice use among Medicare managed care and fee-for-service patients dying with cancer. JAMA, 289(17), 2238-2245.
52. ®: Fatigue. Retrieved November 1, 2007, from http://www.ons.org/outcomes/volume1/fatigue.shtml
53. Mitsudomi, T., Kosaka, T., Endoh, H., Horio, Y., Hida, T., Mori, S., et al. (2005). Mutations of the epidermal growth factor receptor gene predict prolonged survival after geftinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. Journal of Clinical Oncology, 23(11), 2513-2520.
54. Mountain, C.F. (1997). Revisions in the international system for staging lung cancer. Chest, 111(6) 1710-1717.
55. National Cancer Institute. (2007). Surveillance, epidemiology, and end results (SEER) cancer statistics review 1975-2004. Retrieved August 8, 2007, from http://SEER.cancer.gov/CSR/1975_2004/results_merged/sect_15_lung_bronchus.pdf
56. National Cancer Institute. (2008a). Clinical trials. Retrieved June 27, 2008, from http://www.cancer.gov/search/ResultsClinicalTrials.aspx?protocolsearchid=2391839&sort=4&page=3&batchsize=10
57. National Cancer Institute. (2008b). A study comparing bevacizumab therapy with or without erlotinib for frst-line treatment of non-small cell lung cancer (ATLAS). Retrieved June 27, 2008, from http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=459533&version=patient&protocolsearchid=2391839
58. National Comprehensive Cancer Network. (2008a). Practice guidelines in oncology: Non-small cell lung cancer [v.2.2008]. Retrieved July 10, 2008, from http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf
59. National Comprehensive Cancer Network. (2008b). Practice guidelines in oncology: Palliative care [v.1.2008]. Retrieved November 5, 2007, from http://www.nccn.org/professionals/physician_gls/PDF/palliative.pdf
60. National Hospice and Palliative Care Organization. (2006). Facts and fgures-2005 fndings. Retrieved November 1, 2007, from http://www.nhpco.org/fles/public/2005-facts-and-fgures.pdf
61. New York Early Lung Cancer Action Project Investigators. (2007). CT screening for lung cancer: Diagnoses resulting from the New York Early Lung Cancer Action Project. Radiology, 243(1), 239-249.
62. Obasaju, C.K., Conkling, P., Richards, D., Fitzgibbons, J., Arceneau, K.A., & Boehm, L. (2007). A randomized phase III trial of gem-citabine with or without carboplatin in performance status 2 (PS 2) patients (pts) with advanced (stage IIIB with pleural effusion or stage IV) non-small cell lung cancer (NSCLC) [Abstract 7533]. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings, Part I, 25(18S), 392s.
63. Olaussen, K.A., Dunant, A., Fouret, P., Brambilla, E., Andre, F., Haddad, V., et al. (2006). DNA repair by ERCC-1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. New England Journal of Medicine, 355(10), 983-991.
64. Omenn, G.S., Goodman, G.E., Thornquist, M.D., Balmes, J., Cullen, M.R., Glass, A., et al. (1996). Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Effcacy Trial. Journal of the National Cancer Institute, 88 (21), 1550-1559.
65. ® (erlotinib) [package insert]. Retrieved August 27, 2007, from http://www.osip.com/full_PI_tarceva
66. Rice, V.H., & Stead, L. (2006). Nursing intervention and smoking cessation: Meta-analysis update. Heart and Lung, 35(3), 147-163.
67. Rosell, R., Danenberg, K.D., Alberola, V., Bepler, G., Sanchez, J.J., Camps, C., et al. (2004). Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clinical Cancer Research, 10(4), 1318-1325.
68. Sandler, A.B., Gray, R., Brahmer, J., Dowlati, A., Schiller, J.H., Perry, M.C., et al. (2005). Randomized phase II/III trial of paclitaxel (p) plus carboplatin (c) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial-E4599 [Abstract 4]. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, Part I, 23(16S), 2s.
69. ® (docetaxel) [package insert]. Retrieved August 10, 2007, from http://www.taxotere.com/oncology/dosage_administration/dosing_guide.aspx
70. Sardarinia, P., Weyler, J., Colpaert, C., Vermeulen, P., Van Marck, E., & Van Schil, P. (2005). Prognostic value of smoking status in operated non-small cell lung cancer. Lung Cancer, 47(3), 351-359.
71. Schild, S.E., Stella, P.J., Geyer, S.M., Bonner, J.A., McGinnis, W.L., Mailliard, J.A., et al. (2003). The outcome of combined modality therapy for stage III non-small-cell lung cancer in the elderly. Journal of Clinical Oncology, 21(17), 3201-3206.
72. Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., et al. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine, 346(2), 92-98.
73. Schrump, D.S., Altorki, N.K., Henschke, C.L., Carter, D., Turrisi, A.T., & Gutierrez, M.E. (2005). Cancer of the lung. In V.T. Devita, S. Hellman, & S.A. Rosenberg (Eds.), Cancer: Principles and practice of oncology (7th ed., pp. 753-776). Philadelphia: Lippincott Williams and Wilkins.
74. SEER. (2008). Database. Retrieved June 26, 2008, from http://seer.cancer.gov/csr/1975_2005/results_merged/sect_15_lung_bronchus.pdf
75. Shepherd, F.A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O'Rourke, M., et al. (2000). Prospective randomized trial of doc-etaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. Journal of Clinical Oncology, 18(10), 2095-2103.
76. Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T., Huattan, E., Hirsh, V., Thongprasert, S., et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine, 353(2), 123-132.
77. Simon, G., Sharma, A., Li, X., Hazleton, T., Walsh, F., Williams, C., et al. (2007). Feasibil ity and effcacy of molecular analysis- directed individualized therapy in advanced non-small-cell lung cancer. Journal of Clinical Oncology, 25(19), 2741-2746.
78. Socinski, M.A., Novello, S., Sanchez, J.M., Brahmer, J.A., Govindan, R., & Belani, C.P. (2006). Effcacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial [Abstract 7001]. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings, Part I, 24(18S), 364s.
79. Socinski, M.A., Schell, M.J., Peterman, A., Bakri, K., Yates, S., Git-ten, R., et al. (2002). Phase III trial comparing a defned duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. Journal of Clinical Oncology, 20(5), 1335-1343.
80. Treat, J., Belani, C.P., Edelman, M.J., Socinski, M.A., Ansari, R.H., Obasaju, C.K., et al. (2005). A randomized phase III trial of gemcitabine (G) in combination with carboplatin (c) or pacli-taxel (p) versus paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (nsclc): Update of the Alpha Oncology trial (A1-99002L) [Abstract 7025]. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, Part I, 23(16S), 627s.
81. U.S. Environmental Protection Agency. (2007). Health effects of exposure to second-hand smoke. Retrieved July 26, 2007, from http://www.epa.gov/iaq/ets/healtheffects.html
82. Walker, S. (2003). Updates in small cell lung cancer treatment. Clinical Journal of Oncology Nursing, 7(5), 563-568.
83. Wasswa-Kintu, S., Gan, W.Q., Man, S.F., Pare, P.D., & Sin, D.D. (2005). Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: A systematic review and meta-analysis. Thorax, 60(7), 570-575.
84. Williams, K.E., Reeves, K.R., Billing, C.B., Pennington, A.M., & Gong, J. (2007). A double-blind study evaluating the long-term safety of varencicline for smoking cessation. Current Medical Research and Opinion, 23(4), 793-801.
85. Wi nton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., et al. (2005). Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. New England Journal of Medicine, 352(25), 2589-2597.
86. Yamamoto, K., Padilla Alarcon, J., Calvo Medina, V., Garcia-Zarza, A., Pastor Guillen, J., Blasco Armengod, E., et al. (2003). Surgical results of stage I non-small cell lung cancer: Comparison between elderly and younger patients. European Journal of Cardio-Thoracic Surgery, 23(1), 21-25.